MADRIGAL PHARMACEUTICALS, INC. Cost of Revenue
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Cost of Revenue of $4.51 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2025-05-01
- MADRIGAL PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-03-31 was $4.51M.
- MADRIGAL PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2024-03-31 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2024 was $6.23M.
- MADRIGAL PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2023 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2022 was $0.00.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 12 month |
|---|---|---|
| 2025-03-31 | $4.51M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $6.23M 10-K · filed 2025-02-26 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $0.00 10-K · filed 2025-02-26 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |